GLP-1 Receptor Agonists: Beyond Diabetes and Weight Loss
The GLP-1 receptor agonist class — dominated by semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) — has reshaped modern medicine. But the peptide science behind these molecules points to applications far beyond metabolic disease.
The Expanding Therapeutic Horizon
Clinical trials are now exploring GLP-1 agonists for cardiovascular risk reduction, chronic kidney disease, liver fibrosis (NASH/MASH), neurodegenerative conditions including Alzheimer’s and Parkinson’s, and even addiction disorders. The SELECT trial showed semaglutide reduced major adverse cardiovascular events by 20% in overweight patients without diabetes — a landmark result that earned FDA approval for the cardiovascular indication in March 2024.
The Next Generation
Dual and triple agonists are the new frontier. Tirzepatide (GIP/GLP-1) already demonstrated superior weight loss to semaglutide. Retatrutide (GIP/GLP-1/glucagon) from Eli Lilly showed up to 24.2% body weight reduction at 48 weeks in Phase 2 — unprecedented in obesity pharmacotherapy. Oral formulations and once-monthly injectables are also advancing rapidly through pipelines.
Manufacturing Challenges
The peptide synthesis supply chain is under unprecedented strain. Solid-phase peptide synthesis (SPPS) capacity is being expanded globally, with major CMO investments from WuXi STA, Bachem, PolyPeptide Group, and CordenPharma. The complexity of these 30–40 amino acid peptides — often requiring pseudoproline dipeptides and complex purification — keeps barriers to entry high.
What to Watch
The peptide therapeutics market is projected to reach $75 billion by 2030, driven largely by metabolic disease. But the real story is the cascade of new indications being unlocked. Each new approval expands the total addressable market — and stretches an already tight manufacturing base.